34 results about "Colorectal tissue" patented technology

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.

The invention provides a human colorectal cancer protein mark CLCA1 (calcium-activated chloride channel 1) kit, which comprises a specific antibody aiming at CLCA1, an EDTA (ethylene diamine tetraacetic acid) antigen restoration solution, an endogenous peroxidase blocker, goat serum, second antibodies, a PBS buffer solution, hematoxylin and a DAB color developing solution. Study results show that the expression quantity of the CLCA1 in the normal colorectal tissues is obviously higher than that in the colorectal cancer tissues; the content of the CLCA1 in the health people blood is obviously higher than the content in the blood of the colorectal cancer patient; in addition, the lifetime of the colorectal cancer patients with high CLCA1 expression is obviously longer than the patient with low CLCA1 expression; the scientific basis is provided for effectively judging the colorectal cancer canceration progress, detecting the human colorectal cancer in the early stage and judging the prognosis. Therefore the kit provided by the invention is used for preparing a preparation for screening, diagnosing or predicting the human colorectal cancer, can be used for screening anti-colorectal-cancer medicine targets, and are also used for preparing medicine for relieving or treating the human colorectal cancer. The kit provided by the invention is efficient and convenient, and the cost is lower.

The present invention provides a method for establishing an animal model of radiation-induced colorectal inflammation. The method comprises the following steps: mice are randomly divided into two large groups; the mice are normal fed for 1-2 weeks to enable the mice to be adapted to a new living environment; body positions of the mice during irradiation are simulated and an average value is taken;a radiotherapy plan is developed; depending on different group designs, a single large dose radiation is conducted using different doses of gradient rays; and severity of colorectal tissue lesions isassessed. Combining clinical practices, a common therapeutic ray (6MV X ray) used by a medical linear accelerator can better simulate radioactive colorectal injury lesion process of clinical radiotherapy side reactions, and besides, the method is low in animal mortality and simple and easy to repeat, provides an experimental basis for studying the radioactive colorectal injury, is convenient forfurther studying mechanism of the radioactive colorectal injury and guiding clinical medication, closer to clinical practice and more conducive to studying course mechanism of radiation enteritis anddrug development, and can also further expand use of a prevention and treatment technology applied in the radiation enteritis.

The invention discloses an application of target gene DNA methylation as molecular markers in preparation of a kit for distinguishing colorectal tissue canceration progress. The target gene DNA methylation is one or more of COL25A1, GALR1, INHBA and HKDC1 genes. The invention finds for the first time that the DNA methylation molecular markers shown in SEQ ID NO.1-4 can be used for distinguishing the colorectal tissue canceration progress, an obtained model has better identification and diagnosis efficiency, and AUC is 0.662-0.734. The AUC of the model is 0.764 after four target gene DNA methylation markers are combined. The DNA methylation molecular markers have the characteristics of high sensitivity and high specificity when distinguishing rectal polyp and colorectal cancer and can assist in monitoring the process of rectal polyp to colorectal cancer.

The invention discloses a colorectal cancer mismatch repair function prediction method and device, and the method comprises the steps: obtaining an HE staining pathological section of a colorectal tissue, generating a digital pathological image of the HE staining pathological section, dividing the digital pathological image into a plurality of sub-regions, extracting tissue regions in the plurality of sub-regions, classifying tumor areas in a tissue area through a tissue classifier, dividing all tumor areas into MSI areas and MSS areas through an MSI/MSS classification model, calculating the ratio of the number of the MSI areas to the number of the tumor areas, and outputting a prediction result of an HE staining pathological section according to the ratio. Compared with the prior art, the method and the device for predicting the colorectal cancer mismatch repair function have the advantages that the dependence on manpower is reduced, and the efficiency is improved.

The invention belongs to the technical field of biological medicine, and provides a colorectum-targeted drug-loaded exosome and application thereof, and a medicine for treating colorectal diseases. The colorectum-targeted drug-loaded exosome is obtained by introducing the medicine for treating the colorectal diseases into an exosome with a colorectal tissue targeting property; and the exosome with colorectal tissue targeting property is derived from lung cells. A colorectal tumor treatment drug contains the colorectum-targeted drug-loading exosome. Compared with the prior art, the exosome secreted by the lung cells can be enriched in the colorectum without any modification, the exosome derived from the lung cells is used, the problem of exosome yield is solved, and good application prospect is obtained; and different drugs or active molecules can be loaded by using the lung cell-derived exosome, and the treatment effect of colorectal diseases is improved and toxic and side effects of the drugs are reduced through targeted colorectal tissue administration.

The present invention provides an anti-human regenrating gene 4 monoclonal antibody, a preparation method and applications thereof as well as a hybridoma cell line producing the monoclonal antibody. The monoclonal antibody has specificity in respect to the 333th to 743th nucleotide (that is, the nucleotide sequence shown as SEQ ID No.3) encoded polypeptides of the nucleotide sequence shown as SEQ ID No.1. The present invention is mainly characterized in providing the anti-human regenrating gene 4 monoclonal antibody, the preparation method and applications thereof as well as the hybridoma cell line producing the monoclonal antibody, laying a foundation for further crystalizing the expression of Reg 4 in colorectal tissues, and the anti-human regenrating gene 4 monoclonal antibody can be used for the preparation of the early detection kit of colorectal cancer.

A fluorescence endoscopic method for visualization of colorectal tissue using a fluoroquinolone antibiotic and a method for diagnosis of lesions of colorectal tissue using the same. The fluorescence endoscopic method for visualization of colorectal tissue includes staining goblet cells of the colorectal tissue with moxifloxacin, which is a fluoroquinolone antibiotic, and exciting the stained goblet cells with single photons in the near UV region or in the visible region, followed by fluorescence endoscopic photographing of the goblet cells, thereby enabling acquisition of morphological information on living tissue without damage to or destruction of the colorectal tissue, while allowing diagnosis of lesions of the colon based on the morphological information on living tissue such as information on the distribution of the goblet cells. Specifically, the fluorescence endoscopic method includes: a colorectal tissue staining step in which the crypt of the colorectal tissue is stained with a fluoroquinolone antibiotic; an image pickup unit insertion step in which an image pickup unit is inserted into the colon; a light irradiation step in which the colorectal tissue is irradiated with excitation light from a light source of the image pickup unit; a colorectal tissue photographing step in which the colorectal tissue is photographed using a photographing device of the image pickup unit through the fluoroquinolone antibiotic fluorescence-excited by light in the light irradiation step, wherein, in the colorectal tissue staining step, goblet cells of the crypt are stained with the fluoroquinolone antibiotic; in the light irradiation step, the light source emits single photons as excitation light inducing fluorescence of the fluoroquinolone antibiotic, the excitation light from the light source having a wavelength band within the near UV and visible regions; and, in the image pickup unit insertion step, the image pickup unit is a general fluorescence endoscope or a confocal endoscopic microscope.

The invention discloses the application of chemokine CXCL14 in predicting the prognosis of colon cancer, and the application of a reagent for detecting the chemokine CXCL14 in the preparation of a tool for predicting the prognosis of colorectal cancer is included. The invention particularly discloses a method for quantitatively detecting the expression of CXCL14 protein in colorectal tissues through an immunological method to predict the prognosis of the colon cancer. The method has a significant predictive value for the prognosis of the total survival time of a patient with an III-IV colorectal cancer, therefore, the poor treatment prognosis can be improved in a targeted manner, the medical level is improved, and the quality of life is improved.

The invention belongs to the technical field of biological and medical examination, and relates to a molecular biological method for detecting the expression quantity of tumor-related gene products, and the method can be used for providing references for identification of colorectal cancer change, colorectal cancer classification/type, prognosis evaluation and the like. The related genes comprise: KRT23, KRT80, CA9, FOXQ1, CDH3, KIAA1199, CLDN2, KLK10, CLDN1, GRIN2D, NKD1, C6ORF223, MMP3, MMP11, TRIM29, TESC, GYLTL1B, NKD2, PRSS22, VWA2, REG1A, DPEP1, FABP6, CEL, CELP, CPNE7, RPL13AP20, TNFRSF6B, CYP19A1, RPLP0P2, GUCA2B, AQP8, CA1, GUCA2A, CA2, CLCA4, H19, FAP, NAT1 and the like. The combined application of the genes (single or any combination) is beneficial to providing references for identification, classification/type, prognosis evaluation and the like of the colorectal cancer; when the genes are jointly applied to identify colorectal cancer and normal colorectal tissues, the sensitivity can reach 97% when the specificity is 100%.

Methods of inducing apoptosis in hyperproliferative cells, particularly cancer cells are provided. Such method involves increasing the levels of a potassium channel modulatory protein in the cell. Examples of such proteins are native KChAP protein, a biologically active variant of native KChAP protein, or a biologically active KChAP-related protein (collectively referred to hereinafter as “KChAP protein”). In one embodiment, the cells are contacted with the KChAP protein under conditions permitting uptake of the protein by the cells. In another embodiment, the cells are contacted with (i) a nucleic acid encoding the KChAP protein, and (ii) a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the KChAP protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. Methods of detecting cancerous cells in a biological sample selected from the group consisting of a colorectal tissue sample or brain tissue sample are also provided. Such method comprises assaying for the presence of elevated levels of KChAP mRNA or KChAP protein in the sample.